The discovery of vaccine antigens through whole genome sequencing (WGS) contrasts with
the classical hypothesis-driven laboratory-based analysis of microbes to identify …

Recently approved in Europe and Australia, the multi-component meningococcal B vaccine,
4CMenB (Bexsero®, Novartis Vaccines and Diagnostics), contains three surface-exposed …

Abstract Background In September 2015, the four-component, protein-based meningococcal
serogroup B vaccine (4CMenB; Bexsero) became available for private purchase in Spain …

Abstract Background In September 2015, the United Kingdom introduced the
multicomponent meningococcal group B vaccine (4CMenB, Bexsero) into its publicly funded …

Summary Background In September, 2015, the UK became the first country to introduce the
multicomponent group B meningococcal (MenB) vaccine (4CMenB, Bexsero) into a publicly …

The plasmid-mediated colistin resistance gene, mcr-1, was detected in an Escherichia coli
isolate from a Danish patient with bloodstream infection and in five E. coli isolates from …

Background Invasive meningococcal disease (IMD) is a major cause of bacterial meningitis
and septicaemia although infection by some serogroups may be prevented through …

Background Meningococcal serogroup B disease disproportionately affects infants. We
assessed lot-to-lot consistency, safety and immunogenicity, and the effect of concomitant …

Introduction: Neisseria meningitidis serogroup B (MenB) is the most common cause of
bacterial meningitis in many industrialized countries and occurs at any age. The highest …

Abstract Background 4CMenB (Bexsero), a vaccine developed against invasive
meningococcal disease caused by capsular group B strains (MenB), was recently licensed …